GnRH Antagonist SHR7280 clinical trials
Also written SHR7280.
How each study uses GnRH Antagonist SHR7280 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the GnRH Antagonist SHR7280 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Studies
Open first, then newest update. How each study uses GnRH Antagonist SHR7280 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- A Phase II/III Study of Efficacy and Safety of SHR7280 Tablets in Subjects With Menorrhagia With Uterine FibroidsRecruitingPhase 2/3Jiangsu HengRui Medicine Co., Ltd.NCT05442827Written as SHR7280 tablets
- A Phase 1 Clinical Study to Evaluate the Effects of SHR7280 on the Pharmacokinetics of Midazolam, S-warfarin, Omeprazole, Digoxin, and Rosuvastatin in Healthy SubjectsCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT06949124Written as SHR7280 Tablets
- A Trial of SHR7280 in Healthy SubjectsCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT06969664Written as SHR7280 Tablet
- A Study to Evaluate the Mass Balance of [14C]SHR7280 in Healthy Adult VolunteersCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT06408948Written as [14C]SHR7280
- The Pharmacokinetic(PK)/Pharmacodynamics(PD) Study of SHR7280 Tablets in Premenopausal Subjects With Endometriosis.CompletedPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT04417972Written as SHR7280
- Identify Effective Doses of SHR7280 Tablets in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoing Assisted Reproductive Technology (ART)CompletedPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT05082233Written as SHR7280 tablets
- A Clinical Study Evaluating the Relative Bioavailability of SHR7280 Dry Suspension and TabletsCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT05868057Written as SHR7280 tablets
- A Phase 1 Dose Escalation and Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate CancerCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT04995042Written as SHR7280
- The PK/PD Study of SHR7280 Tablets in Healthy Subjects.CompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT04554043Written as SHR7280